Ismahène Benzaïd

544 total citations
10 papers, 454 citations indexed

About

Ismahène Benzaïd is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ismahène Benzaïd has authored 10 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Ismahène Benzaïd's work include Bone health and treatments (8 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Ismahène Benzaïd is often cited by papers focused on Bone health and treatments (8 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Ismahène Benzaïd collaborates with scholars based in France, Finland and Switzerland. Ismahène Benzaïd's co-authors include Philippe Clézardin, Hannu Mönkkönen, Verena Stresing, Florence Daubiné, Jukka Mönkkönen, Edith Bonnelye, Jonathan Green, Jean‐Louis Touraine, Peter I. Croucher and Akeila Bellahcène and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

Ismahène Benzaïd

9 papers receiving 444 citations

Peers

Countries citing papers authored by Ismahène Benzaïd

Since Specialization

Citations

This map shows the geographic impact of Ismahène Benzaïd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ismahène Benzaïd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ismahène Benzaïd more than expected).

Fields of papers citing papers by Ismahène Benzaïd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ismahène Benzaïd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ismahène Benzaïd. The network helps show where Ismahène Benzaïd may publish in the future.

Co-authorship network of co-authors of Ismahène Benzaïd

This figure shows the co-authorship network connecting the top 25 collaborators of Ismahène Benzaïd. A scholar is included among the top collaborators of Ismahène Benzaïd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ismahène Benzaïd. Ismahène Benzaïd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Abstract 5281: Development of a panel of breast cancer patient-derived xenograft models (PDX) with estrogen independence and/or acquired resistance to endocrine treatment 2020 ·Cancer Research ·(unknown), Ismahène Benzaïd, (unknown), (unknown), Bruce A. Littlefield	1
2	Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells 2014 ·Cancer Letters ·(unknown), (unknown), Hannu Mönkkönen, Johanna Räikkönen, Ismahène Benzaïd, Philippe Clézardin, Jukka Mönkkönen, Jorma A. Määttä	9
3	In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement 2012 ·Clinical Cancer Research ·Ismahène Benzaïd, Hannu Mönkkönen, Edith Bonnelye, Jukka Mönkkönen, Philippe Clézardin	43
4	High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo 2011 ·Cancer Research ·Ismahène Benzaïd, Hannu Mönkkönen, Verena Stresing, Edith Bonnelye, Jonathan Green, Jukka Mönkkönen, Jean‐Louis Touraine, Philippe Clézardin	124
5	1074 POSTER Effects of Zoledronic Acid and Denosumab on Human Vy9V62 T-cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells 2011 ·European Journal of Cancer ·Ismahène Benzaïd, Hannu Mönkkönen, Philippe Clézardin	0
6	Bisphosphonates in preclinical bone oncology 2010 ·Bone ·Philippe Clézardin, Ismahène Benzaïd, Peter I. Croucher	34
7	Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase 2010 ·Bone ·Verena Stresing, Pierrick G.J. Fournier, Akeila Bellahcène, Ismahène Benzaïd, Hannu Mönkkönen, Marc Colombel, Frank H. Ebetino, Vincent Castronovo, Philippe Clézardin	76
8	Nitrogen-containing bisphosphonates and human γδ T cells 2010 ·Ismahène Benzaïd, Philippe Clézardin	5
9	Zoledronate-Induced IPP/ApppI (Phosphoantigen) Accumulation in Human Breast Cancer Cells Correlates with Vγ9VΔ2 T Cell-Mediated Cancer Cell Death In Vitro and In Vivo 2010 ·Bone ·Ismahène Benzaïd, Hannu Mönkkönen, Verena Stresing, Edith Bonnelye, Jonathan Green, Jukka Mönkkönen, Philippe Clézardin	4
10	Bisphosphonates in cancer therapy 2007 ·Cancer Letters ·Verena Stresing, Florence Daubiné, Ismahène Benzaïd, Hannu Mönkkönen, Philippe Clézardin	158

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact